Literature DB >> 30267147

Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.

Georg Lurje1, Jan Bednarsch2, Zoltan Czigany2, Iakovos Amygdalos2, Franziska Meister2, Wenzel Schöning2, Tom Florian Ulmer2, Martin Foerster2, Cornelis Dejong2,3, Ulf Peter Neumann2,3.   

Abstract

PURPOSE: Tumor recurrence after liver resection continues to pose a major problem in hepatocellular carcinoma (HCC). Here we aimed to evaluate prognostic markers for disease-free (DFS) and overall survival (OS) in HCC-patients who underwent liver resection in curative intent. Additionally, we investigated the effects of HCC-recurrence in a subgroup of patients.
METHODS: Between 2010 and 2016, 111 patients underwent surgical resection for HCC at our institution. A subgroup of 50 patients showed tumor recurrence (n = 50) during follow-up. The associations of DFS and OS with histopathologic characteristics were assessed using univariable and multivariable Cox regression analyses.
RESULTS: Median DFS was 31 months and median OS was 27 months. Milan criteria (p = 0.045), macrovascular invasion (p = 0.044) and UICC tumor stage (p = 0.003) were independently associated with DFS while macrovascular invasion (p = 0.001) and MELD score (p = 0.010) were independently associated with OS. Tumor recurrence did not show an association with OS (p = 0.228). However, patients with HCC-recurrence who underwent repeat-surgical or interventional treatment showed improved OS compared to patients treated with palliative or sorafenib treatment alone (OS 18 months vs. 2 months; p < 0.001).
CONCLUSION: Tumor recurrence alone is not associated with poor oncological outcome and repeat liver resections as well as local-ablative procedures may help to improve OS in HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; Long-term outcome; Repeat hepatectomy

Mesh:

Year:  2018        PMID: 30267147     DOI: 10.1007/s00423-018-1715-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  31 in total

Review 1.  Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal.

Authors:  Kevin Tri Nguyen; J Wallis Marsh; Allan Tsung; J Jennifer L Steel; T Clark Gamblin; David A Geller
Journal:  Arch Surg       Date:  2010-11-15

Review 2.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

3.  Actual 10-year survival following hepatectomy for hepatocellular carcinoma.

Authors:  Bernardo Franssen; Ghalib Jibara; Parissa Tabrizian; Myron E Schwartz; Sasan Roayaie
Journal:  HPB (Oxford)       Date:  2013-12-24       Impact factor: 3.647

4.  Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation.

Authors:  Andreas Andreou; Marcus Bahra; Moritz Schmelzle; Robert Öllinger; Robert Sucher; Igor M Sauer; Safak Guel-Klein; Benjamin Struecker; Dennis Eurich; Fritz Klein; Andreas Pascher; Johann Pratschke; Daniel Seehofer
Journal:  Clin Transplant       Date:  2016-05-20       Impact factor: 2.863

Review 5.  Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma.

Authors:  Georg Lurje; Mickaël Lesurtel; Pierre-Alain Clavien
Journal:  Dig Dis       Date:  2013-06-17       Impact factor: 2.404

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection.

Authors:  Wilmar de Graaf; Krijn P van Lienden; Sander Dinant; Joris J T H Roelofs; Olivier R C Busch; Dirk J Gouma; Roelof J Bennink; Thomas M van Gulik
Journal:  J Gastrointest Surg       Date:  2010-02       Impact factor: 3.452

8.  Cancer statistics for Hispanics/Latinos, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012 Sep-Oct       Impact factor: 508.702

9.  One thousand fifty-six hepatectomies without mortality in 8 years.

Authors:  Hiroshi Imamura; Yasuji Seyama; Norihiro Kokudo; Atsushi Maema; Yasuhiko Sugawara; Keiji Sano; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2003-11

Review 10.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

View more
  9 in total

1.  Limitations of Nerve Fiber Density as a Prognostic Marker in Predicting Oncological Outcomes in Hepatocellular Carcinoma.

Authors:  Jan Bednarsch; Xiuxiang Tan; Zoltan Czigany; Georg Wiltberger; Roman David Buelow; Peter Boor; Sven Arke Lang; Tom Florian Ulmer; Ulf Peter Neumann; Lara Rosaline Heij
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

Review 2.  Hemorheological and Microcirculatory Factors in Liver Ischemia-Reperfusion Injury-An Update on Pathophysiology, Molecular Mechanisms and Protective Strategies.

Authors:  Norbert Nemeth; Katalin Peto; Zsuzsanna Magyar; Zoltan Klarik; Gabor Varga; Mihai Oltean; Anna Mantas; Zoltan Czigany; Rene H Tolba
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

3.  Intraoperative Transfusion of Fresh Frozen Plasma Predicts Morbidity Following Partial Liver Resection for Hepatocellular Carcinoma.

Authors:  Jan Bednarsch; Zoltan Czigany; Isabella Lurje; Christian Trautwein; Tom Lüdde; Pavel Strnad; Nadine Therese Gaisa; Alexandra Barabasch; Philipp Bruners; Tom Ulmer; Sven Arke Lang; Ulf Peter Neumann; Georg Lurje
Journal:  J Gastrointest Surg       Date:  2020-06-03       Impact factor: 3.452

4.  Indications and Complications of Hepatic Resection Patients at Sher-I-Kashmir Institute of Medical Sciences: An Observational Study.

Authors:  Irfan Kar; Kaif Qayum; Junaid Sofi
Journal:  Cureus       Date:  2021-11-18

5.  The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort.

Authors:  Franziska Alexandra Meister; Georg Lurje; Suekran Verhoeven; Georg Wiltberger; Lara Heij; Wen-Jia Liu; Decan Jiang; Philipp Bruners; Sven Arke Lang; Tom Florian Ulmer; Ulf Peter Neumann; Jan Bednarsch; Zoltan Czigany
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

6.  The Prognostic Role of Glutathione and Its Related Antioxidant Enzymes in the Recurrence of Hepatocellular Carcinoma.

Authors:  Yung-Fang Hsiao; Shao-Bin Cheng; Chia-Yu Lai; Hsiao-Tien Liu; Shih-Chien Huang; Yi-Chia Huang
Journal:  Nutrients       Date:  2021-11-14       Impact factor: 5.717

7.  The role of re-resection in recurrent hepatocellular carcinoma.

Authors:  Jan Bednarsch; Zoltan Czigany; Lara R Heij; Iakovos Amygdalos; Daniel Heise; Philip Bruners; Tom F Ulmer; Ulf P Neumann; Sven A Lang
Journal:  Langenbecks Arch Surg       Date:  2022-05-23       Impact factor: 2.895

8.  Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case-control study.

Authors:  Janis M Lapsley; Vincent Wavreille; Sabrina Barry; Josephine A Dornbusch; Carolyn Chen; Haley Leeper; Judith Bertran; Diane Scavelli; Julius M Liptak; Chris Wood; Shelly Shamir; Claire Rosenbaum; Vincenzo Montinaro; Brandan Wustefeld-Janssens; Allyson Sterman; Colin Chik; Ameet Singh; Josh Collins; Laura E Selmic
Journal:  Vet Comp Oncol       Date:  2022-05-15       Impact factor: 2.385

9.  Risk factors for long-term prognosis of hepatocellular carcinoma patients after anatomic hepatectomy.

Authors:  Ya-Li Tian; Jing-Jing Ji; Lu-Ning Chen; Xin-Long Cui; Shi-Teng Liu; Liang Mao; Yu-Dong Qiu; Bing-Bing Li
Journal:  World J Clin Cases       Date:  2020-02-26       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.